This article explores the medical value of glucagon-like peptide-1 receptor agonist analogs and the potential abuse in obesity treatment.It also provides insights into the use of glucagon-like peptide-1 receptor agonist analogs for non-diabetic obesity and discusses related ethical issues.These issues include the equitable allocation of healthcare resources,the importance of patients'informed consent,and the influence of societal aesthetic standards on medical decision-making.Finally,the article makes recommendations to address these issues,including strengthening prescription regulations,improving public awareness of medications,and ensuring patients'informed consent.These recommendations aim to promote the rational and ethical use of glucagon-like peptide-1 receptor agonist analogs in obesity treatment and to safeguard medical ethics and patient safety.
glucagon-like peptide-1 receptor agonistoff-label drug useweight lossethical analysis
NETL
NSTL
万方数据
